NCT05092009 (IPON-3) is a clinical trial of Tissue and blood in Lung Cancer, sponsored by Maastricht Radiation Oncology.

Who is sponsoring NCT05092009?

NCT05092009 is sponsored by Maastricht Radiation Oncology.

What drugs are being tested in NCT05092009?

Interventions in NCT05092009: Tissue and blood.

What condition does NCT05092009 study?

NCT05092009 studies Lung Cancer.

Is NCT05092009 still recruiting?

NCT05092009 is currently recruiting now. Last updated 15 July 2025.

Last reviewed 2025-07-15 · How we verify

NCT05092009: IPON-3

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lung Cancer Organoids and Patient Derived Tumor Xenografts

Recruiting now Last updated 15 July 2025

What this trial tests

trial testing Tissue and blood in Lung Cancer in 600 participants. Currently enrolling.

Timeline

5 October 2022

Primary endpoint
1 April 2026

1 April 2028

Quick facts

Lead sponsor	Maastricht Radiation Oncology
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	600
Start date	5 October 2022
Primary completion	1 April 2026
Estimated completion	1 April 2028
Sites	3 locations across Netherlands

Drugs / interventions tested

Tissue and blood

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Maastricht Radiation Oncology — full company profile →

Who can join

18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Extra tissue will be taken from patient during a procedure in standard of care. Also, through an existing line, 10ml of extra blood will be drawn. From this material the investigator will try to establish matched normal and primary human lung cancer organoids.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The application of patient-derived organoid in the research of lung cancer.
Li Y, Gao X, Ni C, Zhao B, et al · · 2023 · cited 29× · PMID 36696006 · DOI 10.1007/s13402-023-00771-3
Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.
Mei J, Liu X, Tian HX, Chen Y, et al · · 2024 · cited 25× · PMID 38664597 · DOI 10.1002/ctm2.1656
Lung Organoids-The Ultimate Tool to Dissect Pulmonary Diseases?
Bosáková V, De Zuani M, Sládková L, Garlíková Z, et al · · 2022 · cited 25× · PMID 35912110 · DOI 10.3389/fcell.2022.899368
Lung Cancer Organoids: The Rough Path to Personalized Medicine.
Rossi R, De Angelis ML, Xhelili E, Sette G, et al · · 2022 · cited 21× · PMID 35954367 · DOI 10.3390/cancers14153703
Patient-derived xenograft model in colorectal cancer basic and translational research.
Liu X, Xin Z, Wang K. · · 2023 · cited 16× · PMID 36543756 · DOI 10.1002/ame2.12299
Modeling Liver Development and Disease in a Dish.
Iqbal W, Wang Y, Sun P, Zhou X. · · 2023 · cited 4× · PMID 37958904 · DOI 10.3390/ijms242115921
Bridging the gap: how patient-derived lung cancer organoids are transforming personalized medicine.
Liu C, Shi C, Wang S, Qi R, et al · · 2025 · cited 2× · PMID 40302940 · DOI 10.3389/fcell.2025.1554268
Ex Vivo Intestinal Organoid Models: Current State-of-the-Art and Challenges in Disease Modelling and Therapeutic Testing for Colorectal Cancer.
Randall-Demllo S, Al-Qadami G, Raposo AE, Ma C, et al · · 2024 · cited 1× · PMID 39518102 · DOI 10.3390/cancers16213664

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Maastricht Radiation Oncology trials

Trials by the same sponsor.

NCT07501845 — Registry Maastro Applicator · recruiting
NCT07004582 — Lab Research Using Mini-tumors to Study Prostate Cancer Treatments · not yet recruiting
NCT06024941 — Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung Cancer · Phase 2 · withdrawn
NCT05182437 — Precision Radiation Treatment for Epilepsy (PRECISION) · NA · active not recruiting
NCT02432417 — The Addition of Chloroquine to Chemoradiation for Glioblastoma, · Phase 2 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05092009 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Maastricht Radiation Oncology
Last refreshed: 15 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05092009.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing